NCT01023204View on ClinicalTrials.gov

Phase II Study of Weekly Paclitaxel (BMS-181339) in Patient With Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

68

Participants

Timeline

Start Date

October 31, 2002

Primary Completion Date

July 31, 2005

Study Completion Date

July 31, 2005

Conditions
Breast Cancer
Interventions
DRUG

Paclitaxel

Solution, IV, 100 mg/m², weekly for 6 of 7 weeks, until disease progression or unacceptable toxicity became apparent

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY